Rafiq Rachida, Prins Hendrik J, Boersma Wim G, Daniels Johannes Ma, den Heijer Martin, Lips Paul, de Jongh Renate T
Department of Internal Medicine and Endocrinology, VU University Medical Center, Amsterdam.
Department of Pulmonary Diseases, Northwest Hospital group, Alkmaar.
Int J Chron Obstruct Pulmon Dis. 2017 Aug 28;12:2583-2592. doi: 10.2147/COPD.S132117. eCollection 2017.
Although vitamin D is well known for its function in calcium homeostasis and bone mineralization, several studies have shown positive effects on muscle strength and physical function. In addition, vitamin D has been associated with pulmonary function and the incidence of airway infections. As vitamin D deficiency is highly prevalent in chronic obstructive pulmonary disease (COPD) patients, supplementation might have a beneficial effect in these patients.
To assess the effect of vitamin D supplementation on respiratory muscle strength and physical performance in vitamin D-deficient COPD patients. Secondary outcomes are pulmonary function, handgrip strength, exacerbation rate, and quality of life.
We performed a randomized, double-blind, placebo-controlled pilot trial. Participants were randomly allocated to receive 1,200 IU vitamin D3 per day (n=24) or placebo (n=26) during 6 months. Study visits were conducted at baseline, and at 3 and 6 months after randomization. During the visits, blood was collected, respiratory muscle strength was measured (maximum inspiratory and expiratory pressure), physical performance and 6-minute walking tests were performed, and handgrip strength and pulmonary function were assessed. In addition, participants kept a diary card in which they registered respiratory symptoms.
At baseline, the mean (standard deviation [SD]) serum 25-hydroxyvitamin D (25(OH)D) concentration (nmol/L) was 42.3 (15.2) in the vitamin D group and 40.6 (17.0) in the placebo group. Participants with vitamin D supplementation had a larger increase in serum 25(OH)D compared to the placebo group after 6 months (mean difference (SD): +52.8 (29.8) vs +12.3 (25.1), <0.001). Primary outcomes, respiratory muscle strength and physical performance, did not differ between the groups after 6 months. In addition, no differences were found in the 6-minute walking test results, handgrip strength, pulmonary function, exacerbation rate, or quality of life.
Vitamin D supplementation did not affect (respiratory) muscle strength or physical performance in this pilot trial in vitamin D-deficient COPD patients.
尽管维生素D在钙稳态和骨矿化方面的功能广为人知,但多项研究表明其对肌肉力量和身体功能有积极影响。此外,维生素D与肺功能及气道感染的发生率有关。由于维生素D缺乏在慢性阻塞性肺疾病(COPD)患者中非常普遍,补充维生素D可能对这些患者有益。
评估补充维生素D对维生素D缺乏的COPD患者呼吸肌力量和身体表现的影响。次要结局指标为肺功能、握力、急性加重率和生活质量。
我们进行了一项随机、双盲、安慰剂对照的试验性研究。参与者被随机分配,在6个月内每天接受1200国际单位维生素D3(n = 24)或安慰剂(n = 26)。在基线时以及随机分组后的3个月和6个月进行研究访视。访视期间,采集血液,测量呼吸肌力量(最大吸气和呼气压力),进行身体表现和6分钟步行试验,并评估握力和肺功能。此外,参与者记录一本日记卡,记录呼吸道症状。
在基线时,维生素D组血清25-羟维生素D(25(OH)D)浓度(nmol/L)的均值(标准差[SD])为42.3(15.2),安慰剂组为40.6(17.0)。与安慰剂组相比,补充维生素D的参与者在6个月后血清25(OH)D的升高幅度更大(平均差值(SD):+52.8(29.8) 对 +12.3(25.1),<0.001)。6个月后,主要结局指标,即呼吸肌力量和身体表现,在两组之间没有差异。此外,在6分钟步行试验结果、握力、肺功能、急性加重率或生活质量方面未发现差异。
在这项针对维生素D缺乏的COPD患者的试验性研究中,补充维生素D并未影响(呼吸)肌力量或身体表现。